A novel nomogram for predicting post-operative recurrence for patients with intermediate and high-risk non-muscle invasive bladder cancer after thulium laser resection of bladder tumors or conventional transurethral resection of bladder tumors followed by intravesical bacille Calmette-Guérin immunotherapy.

• Tác giả: Ye An, Zi-Jin Hua, Chen-Qian Liu, Zheng Liu, Jian-Xuan Sun, Shao-Gang Wang, Qi-Dong Xia, Yu-Xi Xiang, Jin-Zhou Xu, Meng-Yao Xu, Si-Han Zhang
• Ngôn ngữ: eng
• Thông tin xuất bản: China : Translational andrology and urology , 2025
• Bộ sưu tập: NCBI
• ID: 470841

Tóm tắt

 BACKGROUND: Post-operative recurrence for patients with intermediate and high-risk non-muscular invasive bladder cancer (NMIBC) is common. This study aims to evaluate the potential factors of tumor recurrence, and construct a novel nomogram to predict the probability of tumor recurrence. METHODS: We retrospectively enrolled patients with intermediate and high-risk NMIBC who received thulium laser resection of bladder tumors (TmLRBT) or transurethral resection of the bladder tumor (TURBT) followed by intravesical bacille Calmette-Guérin (BCG) immunotherapy. The risk factors were screened by the least absolute shrinkage and selection operator (LASSO) regression method. And multivariate logistic regression was applied to recognize the independent risk factors of bladder cancer recurrence. A nomogram was established, and the recurrence probability was calculated based on the model scores. RESULTS: A total of 90 patients with intermediate and high-risk NMIBC were included in this study, of whom 53 underwent TURBT and 37 underwent TmLRBT. During the follow-up period, 22 patients (24.4%) experienced bladder cancer recurrence. Three variables were screened out in the LASSO regression. The multivariate logistic analysis suggested that surgery of TURBT [odds ratio (OR) =6.86760
  95% confidence interval (CI): 1.5048-31.34300] and previous bladder tumor (OR =14.73600
  95% CI: 2.81180-77.23000) were independent risk factors of recurrence, while more BCG treatment sessions (OR =0.26504
  95% CI: 0.12455-0.56398) was independent protective factor of recurrence. CONCLUSIONS: Patients with TURBT and previous bladder tumor history were more likely to develop recurrent bladder cancer, while more BCG treatment sessions was independent protective factor of recurrence.